NasdaqGS:PHVS
NasdaqGS:PHVSPharmaceuticals

Pharvaris (NasdaqGS:PHVS): Reassessing Valuation After RAPIDe-3 Phase 3 Success and Deucrictibant Commercial Progress

Pharvaris (NasdaqGS:PHVS) just flagged a major milestone, with its RAPIDe-3 Phase 3 data set to anchor global marketing applications for deucrictibant, potentially reshaping how hereditary angioedema (HAE) is treated worldwide. See our latest analysis for Pharvaris. Investors seem to be weighing this clinical momentum carefully, with the latest share price at $24.16 and a roughly 30% year to date share price return, while the three year total shareholder return above 220% points to powerful...
NYSE:WMS
NYSE:WMSBuilding

Reaffirmed Guidance and Surging Water-Quality Growth Might Change The Case For Investing In Advanced Drainage Systems (WMS)

In recent months, Brown Brothers Harriman highlighted Advanced Drainage Systems as a key positive contributor to its mid-cap fund after the company delivered better-than-expected sales and earnings, while Barclays reaffirmed a positive analyst stance and the firm reiterated its fiscal 2026 guidance. The business is seeing double-digit organic growth in areas such as water quality and stormwater capture solutions, even as short interest inches higher and insider selling picks up, pointing to...
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

National Vision (EYE): Reassessing Valuation After Upgraded Guidance and New 2030 Profitability Roadmap

National Vision Holdings (EYE) just hit a fresh 52 week high after lifting its full year revenue outlook and unveiling a 2030 growth plan focused on profit expansion and multi year cost savings. See our latest analysis for National Vision Holdings. The rally around the upgraded outlook comes after a powerful run, with a year to date share price return of about 168 percent, even as the 5 year total shareholder return remains negative. This suggests momentum is rebuilding as investors reassess...
NasdaqCM:ASTH
NasdaqCM:ASTHHealthcare

Is Astrana Health’s (ASTH) Bigger Bet on Full-Risk Deals Quietly Rewriting Its Earnings Story?

Earlier this week, Needham initiated coverage of Astrana Health with a Buy rating, highlighting its focus on value-based care growth and an increased shift toward full-risk deals, while recent SEC filings showed Director Thomas Lam exercising options for 29,502 shares worth about US$99,716. The combination of upbeat analyst commentary on Astrana’s performance in value-based models and insider option exercise has drawn attention to how its risk-bearing approach might influence its long-term...
NYSE:BWA
NYSE:BWAAuto Components

Is BorgWarner Still Attractive After a 42% Rally and Strong EV Contract Wins?

If you are wondering whether BorgWarner at around $44 is still a smart way to play the shift to electric and hybrid vehicles, you are not alone. This stock sits right at the crossroads of old school autos and future facing drivetrains. The share price is up 2.7% over the last week and a hefty 42.0% year to date, even after a slightly soft 30 day move of -0.7%, adding to an already strong 32.6% gain over the last year. Those gains have been underpinned by ongoing contract wins with major...
NYSE:SJM
NYSE:SJMFood

What J. M. Smucker (SJM)'s Mixed Quarter and Soft Guidance Means For Shareholders

In its recent quarter, J. M. Smucker reported revenue growth of 2.6% year on year, matching expectations and delivering stronger-than-forecast gross margins, but full-year earnings guidance came in below analyst forecasts. Beneath the headline results, the company’s slow organic revenue progress, falling operating margins, and low returns on invested capital point to persistent profitability pressures and questions over the effectiveness of its growth initiatives. We’ll now examine how this...
NYSE:LNN
NYSE:LNNMachinery

Lindsay (LNN) Valuation Check After Securing $80 Million MENA Irrigation Supply Agreement

Lindsay (LNN) just landed an approximately $80 million supply agreement to deliver Zimmatic irrigation systems and FieldNET technology across the MENA region, with most of that revenue expected to hit the current fiscal year. See our latest analysis for Lindsay. The deal lands as Lindsay’s share price has climbed 11.2% over the past month but still sits below where long term holders might like, with a 1 year total shareholder return of minus 5.3%. This suggests sentiment is stabilizing rather...